Table E1.
Subjects' characteristics for the HMGB1 ELISA
| Characteristic | Healthy control (n = 18) |
Asthma mild-moderate (n = 20) |
Asthma severe (n = 22) |
ANOVA/χ2 test∗ |
|---|---|---|---|---|
| GINA classification, n | GINA 1, n = 5 GINA 2, n = 3 GINA 3, n = 12 |
GINA 4, n = 13 GINA 5, n = 9 |
||
| Age (y)† | 53.0 ± 3.2 | 57.6 ± 3.2 | 57.3 ± 2.6 | P = .51 |
| Sex: male, n (%) | 7 (39) | 12 (60) | 11 (50) | P = .43∗ |
| Atopy, n (%) | 4 (22.2) | 12 (60) | 17 (77) | P = .002∗ |
| Smoking status, current smoker, n (%) | 0 (0) | 1 (5) | 3 (14) | P = .21∗ |
| ICS (μg/d BDP equivalent)‡ | 0 (0) | 200 (400)§ | 1600 (400)§|| | P < .001 |
| Pre-BD FEV1 % predicted‡ | 91.5 (35.6) | 87.0 (25.0) | 72.5 (41.5)§ | P = .03 |
| Pre-BD FEV1/FVC‡ | 74.5 (6.0) | 73.0 (10.5) | 72.0 (15.0) | P = .21 |
| % Sputum neutrophils† | 59.8 ± 5.3 | 58.1 ± 6.6 | 62.7 ± 4.5 | P = .88 |
| % Sputum eosinophils‡ | 0.75 (1.4) | 1.0 (3.3) | 2.8 (13.9)§|| | P = .002 |
| % Sputum epithelial cells‡ | 1.60 (2.3) | 2.25 (4.8) | 1.4 (1.7) | P = .735 |
BDP, Beclometasone dipropionate; FVC, forced vital capacity; ICS, inhaled corticosteroid; pre-BD, prebronchodilator.
∗
χ2 test.
†
Mean ± SEM.
‡
Median (interquartile range).
§
P < .05 vs healthy control.
||
P < .05 vs mild asthma.